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Inhaled nedocromil sodium in symptomatic young 
children born prematurely 
B. Y~~KSEL AND A. GREENOUGH* 
Departments of Thovacic Medicine and Child Health, King’s College Hospital, London, U.K. 
The efficacy of a non-steroidal anti-inflammatory agent (nedocromil sodium, NS) has been assessed in young 
children born prematurely who had recurrent respiratory symptoms at follow-up. In a randomized, 
double-blind cross-over trial, either two puffs of NS (2 mg puff - ‘) or placebo were administered three times 
a day via a spacer device and face mask. Fifteen children, median gestational age 27 weeks, birthweight 1100 g 
and postnatal age 12 months were studied. The symptom score was lower in the last 2 weeks of the active 
period (median score 26) compared to the run-in period (median score 55) and the last 2 weeks of the placebo 
period (median score 50), P<O.Ol. The maximum possible symptom score for a 2-week period was 210. 
Compared to the run-in period, children required fewer days of bronchodilator therapy in the last 2 weeks of 
the active treatment (P<O.Ol), but not in the placebo period. Although results of functional residual capacity 
(FRC) measurements were available on only 13 of the 15 children, these did demonstrate a significant change 
in FRC over the active, but not the placebo, period. These data suggest that NS is a useful prophylactic agent 
for children born prematurely and who are symptomatic at follow-up. 
Introduction Methods 
Recurrent coughing and/or wheezing in the 
first years of life are common amongst children 
born prematurely (l-3). Although regular inhaled 
bronchodilators (4,5) can reduce the occurrence of 
such symptoms, prophylactic medication must be 
considered in a proportion of these children. Inhaled 
steroids do reduce symptoms and bronchodilator 
usage, but there is concern regarding side-effects 
following long-term use (68) particularly in very 
young children. In some prematurely born children, 
sodium cromoglycate (SCG) has also been shown to 
be a useful prophylactic agent (9). Nedocromil 
sodium (NS, Tilade), which is superior in action to 
SCG in adults, has been shown to be efficacious in 
adults (10-12) and school-age children (13-l 5), 
but has not been assessed in younger patients. The 
aims of this study were: (1) to determine if inhaled 
NS alleviated respiratory symptoms in symptomatic 
young children born prematurely, and (2) to identify 
factors influencing any clinical response. 
Children born prematurely with a birthweight less 
than 2.0 kg were eligible for entry into the trial if they 
were less than 3 years of age and had not received 
inhaled steroids. Patients were enrolled into a double- 
blind placebo controlled cross-over trial of 14 weeks 
duration if they wheezed and/or coughed on at least 
3 days per week during a 4-week period, and 
remained symptomatic despite administration of 
regular P-agonists or ipratropium bromide for at 
least 2 weeks. Following a 2-week ‘run-in’ period, 
they were randomly assigned to receive either 6 weeks 
of placebo or active therapy. After that 6-week 
period, the patients switched to the alternative 
therapy for a further 6 weeks. Both placebo and 
active treatment were mint tasting and supplied 
as coded inhalers by Fisons Pharmaceuticals 
(Loughborough, U.K.). Both were administered as 
two puffs (4 mg of nedocromil sodium, Tilade) three 
times a day via a spacer device (Nebuhaler) and a 
face mask (Laerdal infant mask). 
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At study entry and at the end of each of the three 
periods, the patients were examined and a clinical 
history was taken. The parents completed daily diary 
cards throughout all three periods. The occurrence 
and severity of any respiratory symptoms were 
recorded on the diary card; day- or night-time 
cough, day- or night-time wheeze, runny nose. Each 
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category was scored from 0 to 3 (none 0, mild 1, 
moderate 2, severe 3), giving a maximum score of 210 
for a 2-week period. 
If the patient was symptomatic, wheezing with or 
without cough, for more than 24 h, bronchodilator 
therapy was given. This was either a /3,-agonist or 
ipratropium bromide according to the previous pre- 
scription for the child, and was administered in the 
usual dosage until the child was symptom-free for 
24 h. If the patient was admitted to hospital, the 
respiratory symptoms failed to respond to 48 h of 
additional bronchodilator therapy, or parents failed 
to comply with the study protocol, then the child’s 
results were excluded from the analysis. 
At the beginning and end of each 6-week period, 
lung volume was assessed by measurement of func- 
tional residual capacity (FRC) by a helium gas 
dilution technique, as described in detail elsewhere 
(4). An increase in FRC was taken to indicate 
improvement, as in the authors’ previous studies 
(4,5,9,16), and increase in FRC has been associated 
with a reduction in symptoms. To assess the repeat- 
ability of FRC measurements, measurements had 
been made previously in 34 children of similar 
gestational and postnatal age as the study group at 
the beginning and end of a 2-week period. In 30 of 
the infants, FRC was re-measured 4 weeks later. 
They were all asymptomatic and none had received 
bronchodilator therapy at the time of the measure- 
ment. The coefficient of repeatability was calculated 
according to the method of Bland and Altman (17). 
For 2 weeks, it was 15 ml (or 2.3 ml kg- ‘), and for 
6 weeks, it was 18 ml (or 2.6 ml kg- ‘). 
Trial Size 
In a previous study, following 2 weeks of regular 
bronchodilator therapy, 18 children had been 
enrolled into a cross-over study examining the effi- 
cacy of inhaled steroids in prematurely born children 
(18). The results demonstrated that inhaled steroids 
compared to placebo therapy reduced the symptom 
score by 37%. A trial population of 14 children 
enabled detection with 80% power at the 5% level of 
a similar reduction in symptom score from the 
placebo to the active period. 
Analysis 
The symptom score of the run-in period was 
compared to the last 2 weeks of each of the 6-week 
active and placebo periods using a paired Wilcoxon 
signed rank test. Children who had more than a 37% 
reduction in symptom score in the last 2 weeks of 
Table I Comparison between the run-in period and last 2 
weeks of each of the treatment periods 
Run-in Active Placebo 
Symptom score 
Bronchodilator usage 
55*7 50*7 
(22-123) (o’-“;O, (6-l 13) 
lo*$ 
(6-14) (0:;) (O-“lY) 
Values given as median (range). 
*P<O.Ol, ?-not significant, $P=O,O6. 
the active period compared to a similar period in 
the placebo and run-in periods were considered 
responders. Such patients were compared to non- 
responders and differences were assessed for 
statistical significance using the Wilcoxon rank sum 
test. 
Patients 
Twenty children were recruited, but five did not 
complete the study. One was admitted to hospital 
and four failed to comply with the study protocol. 
The 14th and 15th children completed the protocol at 
the same time. The 15 children (six females and nine 
males) had a median birthweight of 1100 g (range 
570-1960 g), gestational age of 27 weeks (range 
23-33 weeks) and postnatal age of 12 months 
(range 8-27 months). The median duration of neo- 
natal ventilation was 10 days (range 0.149 days) and 
of oxygen dependency was 43 days (0.3-161 days). 
Nine children suffered from chronic lung disease 
(CLD), that is they remained oxygen-dependent 
beyond 28 days. Seven patients (46%) had a positive 
family history of atopy. The parents of five children 
smoked and eight children had previously required 
admission to hospital for chest-related problems. 
The study was approved by the King’s College 
Hospital Ethics Committee. 
Results 
There was no significant difference between the 
symptom score of the run-in period and the last 2 
weeks of the placebo period (Table 1, Fig. 1). The 
symptom score, however, was lower in the last 2 
weeks of the active period compared to both the 
run-in period and the last 2 weeks of the placebo 
period, P<O.Ol (Table 1, Fig. 1). The symptom score 
was reduced by a median of 45% in the last 2 weeks 
of the active period compared to the placebo period. 
Fewer days of bronchodilator therapy were required 
Inhaled nedocromil sodium 469 
130 
120 
110 
100 
90 
2 
80 
g 70 
E 2 60 
E” 50 
r3 
40 
30 
20 
10 
0 I -  
Run-in Tilade Placebo 
Fig. I The total symptom scores of the run-in period and 
last 2 weeks of the active and placebo periods are depicted. 
Patients are indicated by linked data points. 
in the last 2 weeks of the active period compared to 
both the run-in period and the last 2 weeks of the 
placebo period (P<O.Ol) (Table 1, Fig. 2) but there 
was no significant difference regarding the days of 
bronchodilator therapy in the placebo period com- 
pared to the run-in period. In eight children, the 
symptom score was reduced by more than 37% 
during the last 2 weeks of the active period, com- 
pared to both the run-in period and the last 2 weeks 
of the placebo period. There were no significant 
differences between children who did and did not 
respond (Table 2). 
Unfortunately, for technical reasons, complete 
FRC results were only available in 13 children. In 
those 13 children, however, there was a significant 
change in FRC over the 6-week active period from a 
median of 31 ml kg- i (range 20-37 ml kg - ‘) to 
36 ml kg- * (range 2744 ml kg- ‘), WO.01. No 
such significant change was seen over the placebo 
period; the respective FRC results were 33 ml kg - ’ 
(range 2540 ml kg- ‘) and 35 ml kg- ’ (range 
20-42 ml kg - ‘). There was no significant difference 
between the FRC results at the beginning of the two 
study periods. 
Discussion 
A significant reduction in symptom score from the 
run-in period to the active period was demonstrated. 
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Fig. 2 Days of bronchodilator usage for the run-in period 
and last 2 weeks of the active and placebo periods are 
demonstrated. Individual patients are indicated by linked 
data points. 
There was no interim washout period, thus the last 
2 weeks of each of the two 6-week study periods were 
compared to avoid contamination of the results by 
any possible prolonged anti-inflammatory effects of 
NS. The authors feel that the reduction in symptom 
score is a valid result as there was also a significant 
reduction in symptoms in the active period compared 
to the placebo period, and an indistinguishable mint- 
flavoured placebo and active therapy were used. 
Previously, NS has been difficult to administer in 
young children due to its burnt taste and smell. In 
addition, although results were only available from 
13 of the 15 children, the significant change in 
FRC over the active, but not the placebo, period 
further suggests that NS did have a positive effect on 
respiratory morbidity in these young children. 
In both animal models (19) and humans (20) NS 
has been shown to inhibit the release of mediators 
from mucosal mast cells. It also decreases broncho- 
constriction in animal models (19). Due to the age of 
the study population, serial measurements of airway 
calibre could not be made reliably, but the signifi- 
cantly reduced number of days of bronchodilator 
usage in the active period would be in keeping with 
the results from the animal models (19). 
There were no significant differences in the charac- 
teristics of responders and non-responders. The 
sample size, however, was small and there were 
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Table 2 Characteristics of the children who responded to nedocromil sodium compared to the 
rest of the group 
Responders Non-responders 
(n=8) (n=7) 
Gestational age (weeks) 28 (23-33) 26 (23-33) ns. 
Mechanical ventilation (days) 14 (0.149) 6 (O.lL20) ns. 
Supplementary oxygen (days) 59 (O&161) 42 (0.3-63) ns. 
<One year of age (n) 3 4 ns. 
Family history of atopy (n) 5 2 n.s. 
Values given as median (range). n.s., not significant. 
trends towards a longer duration of mechanical ven- References 
tilation and oxygen support in the responders as well 
as a greater proportion with positive family history of 
atopy. Increased smooth muscle hypertrophy has 
been associated with neonatal respiratory support 
(211, and at follow-up, such patients have an 
increased airway resistance (22). It is tempting to 
speculate that such abnormalities may have made 
them more responsive to NS. The present trial popu- 
lation was less than 3 years of age. This cut-off 
was deliberately chosen as, up to that age, adverse 
neonatal factors have a significant association with 
respiratory morbidity at follow-up (23). In older 
children born prematurely, however, there is no such 
clear relationship (24) and thus the response to 
therapeutic agents is less predictable. In the present 
population of very young children, postnatal age did 
not seem to have an influence and even patients less 
than 1 year of age benefitted from NS. 
It is concluded that NS provides useful treatment 
for some very young children born prem&urely. In a 
previous study (IS), the authors assessed the ability 
of inhaled beclomethasone to reduce recurrent 
respiratory symptoms and bronchodilator usage in 
children aged less than 2 years. Although these 
studies are not directly comparable, it is interesting to 
note that both agents appeared to have a similar 
magnitude of effect in reducing respiratory symp- 
toms. Thus, whether NS has advantages over other 
prophylactic agents now requires investigation in 
appropriate randomized trials. 
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